Article
Gastroenterology & Hepatology
Cristian Hernandez-Rocha, Shadi Nayeri, Williams Turpin, Mike Steel, Krzysztof Borowski, Joanne M. Stempak, James Conner, Mark S. Silverberg
Summary: This study aimed to establish the prognosis, transcriptional and microbial features of histo-endoscopic remission and activity in ulcerative colitis (UC) patients. The results showed that UC patients with histo-endoscopic remission had a lower risk of relapse and their rectosigmoid mucosa transcriptional profile resembled that of healthy controls. Host genes with antimicrobial properties were significantly associated with mucosal microbiota.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Gastroenterology & Hepatology
Markus F. Neurath, Michael Vieth
Summary: Mucosal healing is an important prognostic factor in the management of patients with inflammatory bowel disease. It can predict clinical remission and resection-free survival. There are two levels of mucosal healing: endoscopic healing and histological healing. Drug therapies and new techniques can have an impact on mucosal healing, but cannot provide a definitive cure.
Review
Gastroenterology & Hepatology
Kentaro Moriichi, Mikihiro Fujiya, Toshikatsu Okumura
Summary: In patients with inflammatory bowel disease, the goals of treatment have shifted towards achieving mucosal healing and deep remission. However, the definition of mucosal healing remains controversial, and new endoscopic procedures may help to assess these goals more accurately in the future. Molecular imaging also has the potential to detect factors associated with deep remission.
DIGESTIVE ENDOSCOPY
(2021)
Article
Gastroenterology & Hepatology
Hunter Wang, Ingrid Fewings, Lee Bornman, Bruce Shadbolt, Mitali Fadia, Kavitha Subramaniam
Summary: Histologic activity is important in predicting future relapse in UC patients. This study found that histologic remission using the NHI score independently predicts longer relapse-free survival and may be a superior therapeutic target than endoscopic remission.
JOURNAL OF CLINICAL GASTROENTEROLOGY
(2023)
Article
Medicine, General & Internal
Fang Chen, Yue Hu, Yi-Hong Fan, Bin Lv
Summary: This study demonstrated the clinical significance of fecal calprotectin in evaluating endoscopic patterns and clinical manifestation in ulcerative colitis patients. The cut-off value of 164 μg/g for FC concentration was found to predict clinical active disease with high sensitivity and specificity. However, further large-scale studies are needed to confirm the reliability of the cut-off value.
FRONTIERS IN MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Keiko Maeda, Masanao Nakamura, Takeshi Yamamura, Tsunaki Sawada, Eri Ishikawa, Akina Oishi, Shuji Ikegami, Naomi Kakushima, Kazuhiro Furukawa, Tadashi Iida, Yasuyuki Mizutani, Takuya Ishikawa, Eizaburo Ohno, Takashi Honda, Masatoshi Ishigami, Hiroki Kawashima
Summary: This study analyzed the usefulness of serum gelsolin as a serological biomarker for clinical and endoscopic activities in ulcerative colitis. The findings indicate that serum gelsolin level correlates with clinical and endoscopic activities in ulcerative colitis, has higher sensitivity and specificity than C-reactive protein, and can detect mucosal healing, suggesting its potential as a biomarker for ulcerative colitis.
Article
Biochemistry & Molecular Biology
Leonie Wittner, Lukas Wagener, Jakob J. Wiese, Iris Stolzer, Susanne M. Krug, Elisabeth Naschberger, Rene Jackstadt, Rudi Beyaert, Raja Atreya, Anja A. Kuehl, Gregor Sturm, Miguel Gonzalez-Acera, Jay V. Patankar, Christoph Becker, Britta Siegmund, Zlatko Trajanoski, Beate Winner, Markus F. Neurath, Michael Schumann, Claudia Guenther
Summary: The paracaspase MALT1 plays a crucial role in mucosal inflammation. It is highly expressed in colonic epithelial cells of UC patients and experimental colitis. Mechanistically, MALT1 protease function inhibits ferroptosis and contributes to NF-kappa B signaling and STAT3 signaling, which are involved in inflammation and tissue healing.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Keiichi Haga, Tomoyoshi Shibuya, Taro Osada, Shunsuke Sato, Yuka Fukuo, Osamu Kobayashi, Toshio Yamada, Daisuke Asaoka, Kentaro Ito, Kei Nomura, Mayuko Haraikawa, Osamu Nomura, Hirofumi Fukushima, Takashi Murakami, Dai Ishikawa, Mariko Hojo, Akihito Nagahara
Summary: This study found that VDZ is effective in the majority of UC patients, with a high rate of mucosal healing even in those who have previously failed biological therapy. Early clinical remission can predict long-term remission, and week 6 can be a useful evaluation point when using VDZ for UC treatment.
Article
Gastroenterology & Hepatology
Toshiyuki Sakurai, Yoshihiro Akita, Haruna Miyashita, Ryosuke Miyazaki, Yuki Maruyama, Tomoko Saito, Mariko Shimada, Takuji Yamasaki, Seiji Arhihiro, Tomohiro Kato, Tomokazu Matsuura, Masahiro Ikegami, Isao Okayasu, Masayuki Saruta
Summary: The effectiveness of prostaglandin E-major urinary metabolite (PGE-MUM) in diagnosing endoscopic, histological, and histo-endoscopic mucosal remission of ulcerative colitis (UC) was evaluated and compared with fecal tests.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Xianyong Gui, Alina Bazarova, Rocio Del Amor, Michael Vieth, Gert de Hertogh, Vincenzo Villanacci, Davide Zardo, Tommaso Lorenzo Parigi, Elin Synnove Royset, Uday N. Shivaji, Melissa Anna Teresa Monica, Giulio Mandelli, Pradeep Bhandari, Silvio Danese, Jose G. Ferraz, Bu'Hussain Hayee, Mark Lazarev, Adolfo Parra-Blanco, Luca Pastorelli, Remo Panaccione, Timo Rath, Gian Eugenio Tontini, Ralf Kiesslich, Raf Bisschops, Enrico Grisan, Valery Naranjo, Subrata Ghosh, Marietta Iacucci
Summary: Histological remission is emerging as a key treatment target in UC, and the development of a simple histological index PHRI showed high correlation with endoscopic activity and clinical outcomes. A deep learning AI system based on PHRI accurately predicted histological remission and differentiated active from quiescent UC, with promising sensitivity, specificity, and accuracy results.
Article
Gastroenterology & Hepatology
Kousaku Kawashima, Naoki Oshima, Kenichi Kishimoto, Masatoshi Kataoka, Mai Fukunaga, Satoshi Kotani, Hiroki Sonoyama, Akihiko Oka, Yoshiyuki Mishima, Hideaki Kazumori, Noriyoshi Ishikawa, Asuka Araki, Shunji Ishihara
Summary: This study aimed to determine the optimal FC cutoff value for predicting HH in UC patients and investigate FC's predictability for prolonged CR. The results showed that FC levels < 82 μg/g can predict HH in UC patients with clinical and endoscopic remission, and low FC also leads to prolonged CR.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Medicine, General & Internal
Keijiro Numa, Kazuki Kakimoto, Yasuyoshi Tanaka, Noboru Mizuta, Naohiko Kinoshita, Kei Nakazawa, Ryoji Koshiba, Yuki Hirata, Kazuhiro Ota, Takako Miyazaki, Shiro Nakamura, Kazuhide Higuchi, Hiroki Nishikawa
Summary: This study evaluated the efficacy of adalimumab (ADA) for maintaining remission in patients with refractory ulcerative colitis (UC). The results showed that switching to ADA after tacrolimus (TAC) therapy can effectively prevent relapse in these patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Medicine, General & Internal
Anuja Pandey, Lea Achrafie, Petya Kodjamanova, Tom Tencer, Jinender Kumar
Summary: This systematic literature review assessed the effects of endoscopic mucosal healing and histologic remission on clinical outcomes in adults with UC. The study found that patients with endoscopic mucosal healing and histologic remission had better relapse-free survival rates, clinical remission rates, steroid-free remission rates, and colectomy avoidance rates. Two studies also reported improved quality-of-life outcomes.
CURRENT MEDICAL RESEARCH AND OPINION
(2022)
Article
Gastroenterology & Hepatology
Neeraj Narula, Emily C. L. Wong, Parambir S. Dulai, John K. Marshall, Vipul Jairath, Walter Reinisch
Summary: This study compared the efficacy of adalimumab and vedolizumab for biologic-naive moderate-severe ulcerative colitis using indirect comparisons of phase 3 clinical trials. The results showed that vedolizumab had a better efficacy at week 6 compared to adalimumab. This suggests that indirect comparisons using patient-level clinical trial data can be used to guide future head-to-head trials and drug positioning in the absence of direct comparisons.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Nutrition & Dietetics
Ammar Hassanzadeh Keshteli, Rosica Valcheva, Cheryl Nickurak, Heekuk Park, Rupasri Mandal, Kendall van Diepen, Karen I. Kroeker, Sander Veldhuyzen van Zanten, Brendan Halloran, David S. Wishart, Karen L. Madsen, Levinus A. Dieleman
Summary: The study reveals that dietary modifications, including increased intake of anti-inflammatory foods and decreased intake of pro-inflammatory foods, are associated with metabolic and microbial changes in ulcerative colitis patients in clinical remission, effectively preventing subclinical inflammation.